These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37657559)

  • 1. 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
    Rutrick D; Learned SM; Boyett B; Hassman D; Shinde S; Zhao Y
    J Subst Use Addict Treat; 2023 Nov; 154():209155. PubMed ID: 37657559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.
    Andorn AC; Haight BR; Shinde S; Fudala PJ; Zhao Y; Heidbreder C; Learned SM; Fox NL; Nadipelli VR; Hassman D; Rutrick D
    J Clin Psychopharmacol; 2020; 40(3):231-239. PubMed ID: 32282418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
    Greenwald MK; Wiest KL; Haight BR; Laffont CM; Zhao Y
    Harm Reduct J; 2023 Dec; 20(1):173. PubMed ID: 38042801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.
    Ling W; Nadipelli VR; Solem CT; Ronquest NA; Yeh YC; Learned SM; Mehra V; Heidbreder C
    J Addict Med; 2019; 13(6):442-449. PubMed ID: 30844878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.
    Boyett B; Nadipelli VR; Solem CT; Chilcoat H; Bickel WK; Ling W
    J Addict Med; 2023 Mar-Apr 01; 17(2):182-189. PubMed ID: 36111991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.
    Mariani JJ; Dobbins RL; Heath A; Gray F; Hassman H
    Am J Addict; 2024 Jan; 33(1):8-14. PubMed ID: 37936553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
    Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
    [No Abstract]   [Full Text] [Related]  

  • 11. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
    Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
    Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.
    Ling W; Nadipelli VR; Aldridge AP; Ronquest NA; Solem CT; Chilcoat H; Albright V; Johnson C; Learned SM; Mehra V; Heidbreder C
    J Addict Med; 2020; 14(5):e233-e240. PubMed ID: 32187112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.
    Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L;
    Int J Drug Policy; 2024 May; 127():104390. PubMed ID: 38522175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study.
    Ling W; Nadipelli VR; Solem CT; Ronquest NA; Yeh YC; Learned SM; Mehra V; Heidbreder C
    J Subst Abuse Treat; 2020 Mar; 110():1-8. PubMed ID: 31952623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
    Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.
    Marsden J; Kelleher M; Gilvarry E; Mitcheson L; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hardy W; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Vanderwaal R; Wareham A; Hughes D; Hoare Z
    EClinicalMedicine; 2023 Dec; 66():102311. PubMed ID: 38045803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.
    Lowry N; Cowden F; Day E; Gilvarry E; Johnstone S; Murray R; Kelleher M; Mitcheson L; Marsden J
    BMJ Open; 2022 Oct; 12(10):e067194. PubMed ID: 36270754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.
    Greiner MG; Shulman M; Scodes J; Choo TH; Pavlicova M; Opara O; Campbell ANC; Novo P; Fishman M; Lee JD; Rotrosen J; Nunes EV
    Subst Use Misuse; 2022; 57(11):1732-1742. PubMed ID: 35975917
    [No Abstract]   [Full Text] [Related]  

  • 20. Extended-release naltrexone for youth with opioid use disorder.
    Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
    J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.